secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001213900-23-062780
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Q2 net loss $11.3M; TARA-002 trials on track; cash runway into 2025
---------------------------------------------------------------------------

- Net loss Q2 2023: $11.3M ($1.00/share) vs $8.5M ($0.76) in Q2 2022
- Cash, equivalents $80.4M; expected to fund operations into 2025
- R&D expenses $7.2M, up from $3.1M YoY on TARA-002 clinical costs
- Preliminary TARA-002 NMIBC expansion results expected 1H24; ADVANCED-2 and LM trial start 4Q23

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023062780/0001213900-23-062780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023062780/ea182633-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-062780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer